Clinical effects and gut microbiota changes of using probiotics, prebiotics or synbiotics in inflammatory bowel disease : a systematic review and meta-analysis
© 2021. Springer-Verlag GmbH, DE part of Springer Nature..
PURPOSE: Probiotics have been reported to be beneficial for inflammatory bowel disease (IBD), but the types, number of strains, dosage, and intervention time of probiotics used remain controversial. Furthermore, the changes of gut microbiota in IBD's patients are also intriguing. Thus, this meta-analysis was to explore the clinical effects and gut microbiota changes of using probiotics, prebiotics and synbiotics in IBD.
METHODS: The search was performed in PubMed, Web of Science and the Cochrane library from inception to April 2020. Qualified randomized controlled trials were included. IBD's remission rate, disease activity index and recurrence rate were extracted and analyzed. Changes in the gut microbiota of patients with IBD are comprehensively described.
RESULTS: Thirty-eight articles were included. Probiotics, prebiotics and synbiotics can induce/maintain IBD's remission and reduce ulcerative colitis (UC) disease activity index (RR = 1.13, 95% CI 1.02, 1.26, P < 0.05; SMD = 1.00, 95% CI 0.27, 1.73, P < 0.05). In subgroup analyses of IBD remission rate and UC disease activity index, we obtained some statistically significant results in some subgroup (P < 0.05). To some extent, probiotic supplements can increase the number of beneficial bacteria (especially Bifidobacteria) in the intestinal tract of patients with IBD.
CONCLUSIONS: Our results support the treatment of IBD (especially UC) with pro/pre/synbiotics, and synbiotics are more effective. Probiotic supplements that are based on Lactobacillus and Bifidobacterium or more than one strain are more likely to be beneficial for IBD remission. The dose of 1010-1012 CFU/day may be a reference range for using probiotics to relieve IBD.
| Errataetall: | |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:60 |
|---|---|
| Enthalten in: |
European journal of nutrition - 60(2021), 5 vom: 26. Aug., Seite 2855-2875 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Zhang, Xiao-Feng [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Gut microbiota |
|---|
| Anmerkungen: |
Date Completed 14.07.2021 Date Revised 17.10.2023 published: Print-Electronic ErratumIn: Eur J Nutr. 2021 May 24;:. - PMID 34028591 Citation Status MEDLINE |
|---|
| doi: |
10.1007/s00394-021-02503-5 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM321158873 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM321158873 | ||
| 003 | DE-627 | ||
| 005 | 20231225175221.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s00394-021-02503-5 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1070.xml |
| 035 | |a (DE-627)NLM321158873 | ||
| 035 | |a (NLM)33555375 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Zhang, Xiao-Feng |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Clinical effects and gut microbiota changes of using probiotics, prebiotics or synbiotics in inflammatory bowel disease |b a systematic review and meta-analysis |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 14.07.2021 | ||
| 500 | |a Date Revised 17.10.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a ErratumIn: Eur J Nutr. 2021 May 24;:. - PMID 34028591 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2021. Springer-Verlag GmbH, DE part of Springer Nature. | ||
| 520 | |a PURPOSE: Probiotics have been reported to be beneficial for inflammatory bowel disease (IBD), but the types, number of strains, dosage, and intervention time of probiotics used remain controversial. Furthermore, the changes of gut microbiota in IBD's patients are also intriguing. Thus, this meta-analysis was to explore the clinical effects and gut microbiota changes of using probiotics, prebiotics and synbiotics in IBD | ||
| 520 | |a METHODS: The search was performed in PubMed, Web of Science and the Cochrane library from inception to April 2020. Qualified randomized controlled trials were included. IBD's remission rate, disease activity index and recurrence rate were extracted and analyzed. Changes in the gut microbiota of patients with IBD are comprehensively described | ||
| 520 | |a RESULTS: Thirty-eight articles were included. Probiotics, prebiotics and synbiotics can induce/maintain IBD's remission and reduce ulcerative colitis (UC) disease activity index (RR = 1.13, 95% CI 1.02, 1.26, P < 0.05; SMD = 1.00, 95% CI 0.27, 1.73, P < 0.05). In subgroup analyses of IBD remission rate and UC disease activity index, we obtained some statistically significant results in some subgroup (P < 0.05). To some extent, probiotic supplements can increase the number of beneficial bacteria (especially Bifidobacteria) in the intestinal tract of patients with IBD | ||
| 520 | |a CONCLUSIONS: Our results support the treatment of IBD (especially UC) with pro/pre/synbiotics, and synbiotics are more effective. Probiotic supplements that are based on Lactobacillus and Bifidobacterium or more than one strain are more likely to be beneficial for IBD remission. The dose of 1010-1012 CFU/day may be a reference range for using probiotics to relieve IBD | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Meta-Analysis | |
| 650 | 4 | |a Systematic Review | |
| 650 | 4 | |a Gut microbiota | |
| 650 | 4 | |a Inflammatory bowel disease | |
| 650 | 4 | |a Prebiotics | |
| 650 | 4 | |a Probiotics | |
| 650 | 4 | |a Remission | |
| 650 | 4 | |a Synbiotics | |
| 650 | 7 | |a Prebiotics |2 NLM | |
| 700 | 1 | |a Guan, Xiao-Xian |e verfasserin |4 aut | |
| 700 | 1 | |a Tang, Yu-Jun |e verfasserin |4 aut | |
| 700 | 1 | |a Sun, Jin-Feng |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Xiao-Kai |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Wei-Dong |e verfasserin |4 aut | |
| 700 | 1 | |a Fan, Jian-Ming |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t European journal of nutrition |d 1999 |g 60(2021), 5 vom: 26. Aug., Seite 2855-2875 |w (DE-627)NLM102710678 |x 1436-6215 |7 nnns |
| 773 | 1 | 8 | |g volume:60 |g year:2021 |g number:5 |g day:26 |g month:08 |g pages:2855-2875 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s00394-021-02503-5 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 60 |j 2021 |e 5 |b 26 |c 08 |h 2855-2875 | ||